Ainos licenses VELDONA worldwide to BioPhoenix; $600K upfront, up to ~$10M in fees plus 25% sublicense revenue

Ainos, Inc.

Ainos granted BioPhoenix an exclusive, worldwide license to VELDONA for Sjögren's disease and thrombocytopenia; $600,000 upfront fee due within 15 business days after delivery conditions.
BioPhoenix pays a one-time first-sublicense fee and 25% of applicable net sublicensing revenue; licensing all 15 additional indications would bring total fees to ~$10.0M.
BioPhoenix funds and executes clinical/regulatory development, reducing Ainos' independent capital needs; Ainos retains platform ownership and prioritizes AI Nose/Chemical Intelligence.
Ainos is barred from competing in the licensed indications worldwide during the term and for 10 years after; term runs to later of last patent expiry or 20 years post-9/24/2026.
VELDONA history: 68 studies (3 Phase I, 63 Phase II, 2 Phase III), 16 indications, ~6,000 participants; Sjögren's had ~497 patients in two Phase III trials.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.